COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #151 of 230
10/8 Late treatment study
Aparisi et al., medRxiv, doi:10.1101/2020.10.06.20207092 (Preprint)
Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19
Source   PDF   Share   Tweet
Retrospective 654 hospitalized patients focused on low-density lipoprotein cholesterol levels, also showing results for HCQ with 605 HCQ patients, unadjusted 30 day mortality relative risk RR 0.37, p = 0.008.

Aparisi et al., 10/8/2020, prospective, Spain, Europe, preprint, 18 authors.
risk of death, 63.0% lower, RR 0.37, p = 0.008, treatment 122 of 605 (20.2%), control 27 of 49 (55.1%).
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.